Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series.

Medicine (Baltimore)

Médecine Interne, Groupe Hospitalier Timone, AP-HM, Aix-Marseille Université, Marseille Médecine Interne, Hopital Cochin, Université Paris-Descartes, Paris Médecine Interne, Centre hospitalier de Pau, Pau CHRU-Hôpital Claude Huriez, Université de Lille, Lille Médecine Interne, Groupe hospitalier Pitie Salpêtrière AP-HP, Université Pierre et Marie Curie, Paris Médecine interne, CHU le Bocage, Université de Bourgogne, Dijon Médecine Interne, CHU Rennes, Rennes Médecine interne, CHU Mondor, Créteil CHG Saint Denis de la Réunion, Réunion, France.

Published: March 2017

IgG4-related disease (IgG4-RD) is characterized by variable tissue or organ involvements sharing common pathological findings. Orbital or orbital adnexa involvement of the disease has been reported in a few case series. The aim of our study was to characterize and analyze ophthalmic manifestations from a nationwide French case-series.Patients with IgG4-RD and orbital or orbital adnexa involvement included in the French multicentric IgG4-RD case-registry were identified. Only patients fulfilling "modified" comprehensive diagnostic criteria with pathological documentation were retained for the study. Clinical, biological, pathological, radiological findings and data regarding the response to treatment were retrospectively analyzed.According to our data registry, the frequency of IgG4-related ophthalmic disease (IgG4-ROD) was 17%. Mean age at diagnosis was 55.1 ± 7.1 years with a male/female ratio of 2.2. The 19 cases of IgG4-ROD consisted of lacrimal gland (68.4%), soft tissue (57.9%), extra-ocular muscles (36.8%), palpebral (21.1%), optical nerve (10.5%), orbital bone (10.5%), and mononeuritis (V1 and/or V2, 10.5%) involvements. IgG4-ROD was bilateral in 57.9% of cases. Extra-ophthalmic manifestations were reported in 78.9% of cases. All patients responded to prednisone but two-thirds of patients relapsed within a mean (SD) of 9.8 (3.5) months and 72.2% required long-term glucocorticoids and/or immunosuppressive agents. Eight patients were treated by rituximab with a favorable response in 87.5% of cases.Lacrimal involvement is the most frequent ophthalmic manifestation of IgG4-RD and is frequently associated with extra-orbital manifestations. Despite initial favorable response to steroids, the long-term management of relapsing patients needs to be improved.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348160PMC
http://dx.doi.org/10.1097/MD.0000000000006205DOI Listing

Publication Analysis

Top Keywords

ophthalmic manifestations
8
igg4-related disease
8
response treatment
8
orbital orbital
8
orbital adnexa
8
adnexa involvement
8
favorable response
8
orbital
5
patients
5
ophthalmic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!